The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Acquires a highly selective and brain penetrant NLRP3 inhibitor from Mwyngil Therapeutics Company's lead candidate BT-267, a ...

Roivant Sciences' 44% return highlights potential in its pipeline and partnerships. I maintain a cautious stance on RIOV ...

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion ...

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

The funding will be deployed over a three-year period from 2025 to 2027, enabling Alfasigma to significantly advance its R&D ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

DelveInsight’s Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to ...

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.